GLP‐1RAs were associated with a significant reduction in CRC risk compared to thiazolidinediones (RR: 0.82, 95% CI: 0.68–0.96), insulin (RR: 0.57, 95% CI: 0.32–0.81), and SGLT2 inhibitors (RR: 0.77, 95% CI: 0.59–0.95). This evidence concerns the gene INS and colorectal carcinoma.